ABSTRACT
Background & aims Hepatic manifestations of coronavirus disease 2019 (COVID-19) are common among people infected with hepatitis B virus (HBV) and hepatitis C virus (HCV). This systematic review aimed to summarize the evidence on COVID-19 patients with HBV or HCV co-infections.
Methods We searched multiple electronic databases and preprint servers from December 1, 2019 to August 9, 2020. Studies were included if they reported quantitative empirical data on COVID-19 patients with HBV or HCV co-infections. Descriptive analyses were reported and data were narratively synthesized. Quality assessments was completed using the Joanna Briggs Institute critical appraisal tools.
Results Out of the 941 identified records, 28 studies were included. Of the eligible studies, 235 patients with COVID-19 were infected with HBV and 22 patients with HCV. Most patients were male and mean age was 49.8 and 62.8 in patients with HBV and HCV, respectively. Death proportion was 6% among COVID-19-HBV and 13% among COVID-19-HCV co-infected patients. Among COVID-19 patients, 34.1% and 76.2% reported at least one comorbidity besides HBV and HCV infections, mainly hypertension and diabetes mellites type 2. The most common COVID-19-related symptoms in both HBV and HCV groups were fever, cough and dyspnea. ICU admission was reported in 14.1% and 21.4% of individuals with HBV and HCV, respectively.
Conclusions Our findings suggest a considerable risk of morbidity and mortality among COVID-19 patients with HBV and HCV. Careful assessment of hepatic manifestations upon admission of patients could help improve health outcomes among COVID-19 patients with HBV or HCV co-infections.
Key Points
Hepatic manifestations of COVID-19 are common among people infected with HBV and HCV.
Among COVID-19 patients, 34.1% and 76.2% reported at least one comorbidity besides HBV and HCV infections.
The most common COVID-19-related symptoms in both HBV and HCV groups were fever, cough and dyspnea.
There is a considerable risk of mortality among COVID-19 patients with HBV and HCV.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Clinical Protocols
Funding Statement
No funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA; This is a systematic review
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of all authors: Hossein Mirzaie: hosseinmirzaei64{at}yahoo.com
Mohammad Vahidi: mammad.vahidi{at}gmail.com
Mostafa Shokoohi: shokouhi.mostafa{at}gmail.com
Maryam Darvishian: mdarvishian{at}bccrc.ca
Hamid Sharifi: sharifihami{at}gmail.com
Heidar Sharafi: heidarsharafi{at}gmail.com
Mohammad Karamouzian: Karamouzian.m{at}alumni.ubc.ca
Funding statement: Authors received no funding to conduct this review.
Conflict of interest disclosure: Authors have no potential conflict of interest to declare.
Ethics approval statement: None required given the secondary nature of the study.
Patient consent statement: Not applicable given the secondary nature of the study.
Permission to reproduce material from other sources: Not applicable.
Data Availability
All data is presented in the paper
